HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nominations To Lead FDA Coming Soon For Hamburg And Sharfstein

This article was originally published in The Rose Sheet

Executive Summary

The White House is set to nominate former New York City Health Commissioner Margaret Hamburg as FDA commissioner, according to sources knowledgeable about the selection process

You may also be interested in...

Hamburg Joins Sharfstein On FDA Commissioner Shortlist

The removal of Duke University cardiologist Robert Califf's name from consideration for FDA commissioner indicates that a record of government service and a strong public health background will trump all other qualifications for the post

Obama Wants FDA’s “Full Review” As Recall Of Peanut Butter Items Goes On

FDA is due for a "full review" in light of a salmonella outbreak that has sickened more than 500 people, possibly killed eight, and prompted a massive recall of peanut butter products, according to President Obama

Medicare-For-Hmmm: A Year Of House Hearings Show Democratic Disunity

Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts